Ligases Enzyme Global Market Report 2024

The ligases enzyme market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.21 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed in the historic period of ligase enzymes can be attributed to several factors. Initially, the discovery and development of ligase enzymes played a crucial role in their increased utilization. Additionally, the growth of the biotechnology industry provided a conducive environment for the advancement and application of ligase enzymes. A heightened understanding of DNA repair mechanisms further contributed to their significance in various cellular processes. The expansion of genetic engineering applications, facilitated by ligase enzymes, also played a role in their increased demand. Lastly, the rise in demand for molecular diagnostics, where ligase enzymes find application, further fueled their growth during this historic period.

The ligases enzyme market size is expected to see rapid growth in the next few years. It will grow to $4.92 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth during the forecast period can be ascribed to the expanding applications of personalized medicine, a heightened emphasis on synthetic biology, the increasing use of ligase enzymes in drug development, a rising demand for molecular diagnostics, and the integration of ligases in next-generation sequencing. Key trends in the forecast period encompass the development of engineered ligases tailored for specific applications, the incorporation of ligase enzymes in CRISPR-based technologies, the customization of ligase-based assays for both research and diagnostics, the emergence of ligase-based isothermal amplification methods, and the adoption of ligase chain reaction (LCR) in diagnostic assays.

The anticipated growth of the ligase enzyme market is attributed to the increasing prevalence of cancer and genetic disorders. Cancer, characterized by uncontrolled cell growth, and genetic disorders, resulting from abnormalities or mutations in genetic material, particularly DNA, are on the rise. Ligase enzymes, crucial for DNA replication, repair, and recombination, play a pivotal role in these conditions. In cancer, ligases repair damaged DNA, contributing to uncontrolled cell growth, while in genetic disorders, ligases can be utilized to target and eliminate affected cells. Notably, in 2020, the Centers for Disease Control and Prevention reported 1,603,844 new cancer cases and 602,347 related deaths in the United States. Additionally, Gene People UK revealed that 1 in 25 children in the UK is affected by a genetic condition, with over 2.4 million individuals living with such disorders.

An upsurge in research and development (R&D) activities is expected to drive the ligase enzyme market's growth. Ligase enzymes, also known as DNA ligases, are essential tools in joining DNA molecules - a critical aspect of various R&D endeavors across diverse fields. For instance, in 2020, the National Center for Science and Engineering Statistics reported a total of $717.0 billion spent on R&D in the United States, with an estimated $791.9 billion for 2021. This increase in R&D investment underscores the significance of ligase enzymes in advancing scientific and technological innovations, thereby fueling the growth of the ligase enzyme market.

Product innovation is emerging as a notable trend in the ligase enzyme market, with major companies actively pursuing the development of novel ligases to solidify their market positions. A prime example is ArcticZymes Technologies ASA, a Norway-based biotechnology firm, which unveiled the ArcticZymes R2D Ligase in December 2021. This patent-pending ligase demonstrates unique specificity, allowing the ligation of DNA to both ends of RNA using a DNA splint. Anticipated to have broad applications in molecular diagnostics, next-generation sequencing, and gene/RNA synthesis for potential therapeutic uses, this enzyme stands out for its high activity and efficiency, making it suitable for diverse applications.

Strategic partnerships are also becoming a focal point for major companies in the ligase enzyme market. Lonza Group, a Switzerland-based company operating in the pharmaceutical, biotechnology, and nutrition sectors, formed a partnership with Singzyme, a Singapore-based company specializing in enzyme development, in September 2021. This collaboration grants Lonza access to Singzyme's enzymatic conjugation platform, enabling site-specific binding of payloads with peptidic linkers to proteins - particularly advantageous for precision medicine applications such as cancer treatment. The ligase-specific tag sequence-based technique ensures versatility in handling various payload types and shorter development timescales.

In May 2022, QIAGEN N.V., a Germany-based provider of molecular testing solutions, acquired a majority stake in BLIRT S.A., a Poland-based biotechnology company known for manufacturing specialty ligase enzymes and reagents. This strategic acquisition is aimed at expanding QIAGEN's sample technology business by leveraging BLIRT's technology and expertise, thereby reinforcing QIAGEN's position in the life science industry. This strategic maneuver underscores the importance of inorganic growth strategies for gaining a competitive edge in the dynamic ligase enzyme market.

Major companies operating in the ligases enzyme market report are BASF SE, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson And Company (BD), Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Novo Holdings AS, GenScript, VWR International, R And D Systems Inc., Promega Corporation, Oxford Nanopore Technologies Limited, Takara Bio Inc., New England Biolabs Inc., BioVision Inc., Enzo Life Sciences, Zymo Research, LGC Biosearch Technologies, Genetix Biotech Asia Pvt. Ltd., BLIRT S.A., Jena Bioscience, Bioline, Creative Enzymes, ArcticZymes Technologies ASA.

North America was the largest region in the ligases enzyme market in 2023. Asia-Pacific is expected to be the fastest-growing region in the ligases enzyme market report during the forecast period. The regions covered in the ligases enzyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ligases enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key types of ligase enzyme products include E. coli DNA ligase, T4 DNA ligase, mammalian ligases, and thermostable ligases. E. coli DNA ligase specifically refers to an enzyme sourced from Escherichia coli (E. coli) bacteria. These ligases are derived from diverse organisms, including microorganisms, animals, and plants. They are integral to a multitude of techniques, encompassing ligase chain reaction (LCR), ligase detection reaction (LDR), next-generation sequencing (NGS), repeat expansion detection (RED), rolling circle amplification (RCA), proximity ligation assay (PLA), molecular cloning, ligation-mediated PCR, and mutation detection. These versatile applications cater to a broad spectrum of end-users, including research laboratories and institutions, pharmaceutical and biopharmaceutical companies, as well as diagnostic laboratories.

The ligases enzyme market research report is one of a series of new reports that provides ligases enzyme market statistics, including ligases enzyme industry global market size, regional shares, competitors with a ligases enzyme market share, detailed ligases enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the ligases enzyme industry. This ligases enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. 

The ligases enzyme market consists of sales of hi-t4 DNA ligase, splintR ligase, salt-t4 DNA ligase, t7 DNA ligase, quick ligation kits, Taq DNA ligase, and electroLigase. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.